ARTICLES BY CYNDI ROOT
-
Weekly FDA Enforcement Report For Drugs 12/17/1412/26/2014
The Food and Drug Administration (FDA) has released its Drug product Enforcement Report for December 17, 2014.
-
ProMetic Licenses Plasma Therapeutics To Generium For Russian Market12/26/2014
ProMetic Life Sciences has licensed its plasma purification system and derived pharmaceuticals to Generium.
-
Ono, Gilead Partner On Treatments For B-cell Malignancies12/26/2014
Ono Pharmaceutical and Gilead Sciences have partnered on ONO-4059.
-
The Medicines Company, SciClone Pharma Partner On Cardiovascular Treatments In China12/23/2014
The Medicines Company and SciClone Pharmaceuticals have partnered on two cardiovascular products in China. The companies announced the deal in a press release, stating that The Medicines Company has granted SciClone an exclusive license to market Angiomax (bivalirudin) and Clevipres (clevidipine) in China.
-
Strategic Science And Technologies Options U.S. Rights To Topical Ibuprofen12/22/2014
Strategic Science and Technologies LLC (SST) announced that it has optioned its topical ibuprofen (SST-0225) to an over-the-counter (OTC) healthcare company.
-
Sorrento, NantWorks Partner To Develop Cancer Immunotherapies12/22/2014
Sorrento Therapeutics has partnered with NantWorks to jointly develop immunotherapies for cancer and auto-immune diseases.
-
Curie-Cancer, GamaMabs Pharma Extend Partnership On Cancer mAbs12/22/2014
Curie-Cancer and GamaMabs Pharma have extended their partnership to find monoclonal antibodies to treat cancer.
-
Galapagos, Janssen Dissolve Partnership On GLPG1205 For Ulcerative Colitis12/19/2014
Galapagos NV and Janssen have decided not to move forward together in their joint development of GLPG1205. Galapagos announced the decision in a press release, stating that the agent is entering a Phase II study for the treatment of ulcerative colitis.
-
DURECT Licenses SABER Technology To Santen Pharmaceutical For Ophthalmology Drug12/19/2014
DURECT and Santen Pharmaceutical have entered into an agreement to use DURECT’s SABER technology to develop and commercialize a sustained release ophthalmology product.
-
OPKO, Pfizer Partner On Long-Acting Human Growth Hormone12/19/2014
OPKO Health and Pfizer have partnered on OPKO's long-acting hGH-CTP. The companies announced the deal in a press release, stating that the agent is for the treatment of growth hormone deficiency (GHD) in adults and children.